Equity Profile

LLY

Eli Lilly and Company

Health CarePharmaceuticals$1.0T

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Eli Lilly and Company (LLY) is a major player in the pharmaceuticals sector, focusing on innovative medicines to treat various health conditions. With a market cap of $1.03 trillion, the company is significant in the healthcare landscape, especially as it navigates the evolving demands for effective treatments and therapies.

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

$6.55

Revenue

Total revenue is essential for understanding the company's sales performance and growth trajectory.

$20.7B

Wall Street expectations, options signals, track record, and call prep available with Pro.

LLY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.79%

Avg Stock Reaction

+0.58%

Last Quarter Recap

In Q1 2026, Eli Lilly reported an EPS of $8.55, significantly exceeding analyst expectations of $7.06, resulting in a stock increase of 9.80% the following day. The company continues to demonstrate strong financial performance amid a competitive pharmaceutical landscape.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Eli Lilly to report strong earnings again, with a consensus EPS of $6.55. Given the company's recent performance, there is optimism about continued revenue growth.

Bull Case

If Eli Lilly exceeds EPS expectations, it could signal robust demand for its products, potentially leading to further stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects, leading to a decline in stock value.

Key Metrics to Watch

EPS

$6.55

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

$20.7B

Total revenue is essential for understanding the company's sales performance and growth trajectory.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Eli Lilly's EPS exceed the consensus estimate of $6.55?

A strong EPS could reinforce investor confidence and lead to a positive stock reaction.

What insights will management provide regarding revenue growth trends?

Understanding revenue drivers will be critical for assessing the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Eli Lilly's ability to leverage recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

Eli Lilly has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing in a significant move, suggesting that investors expect volatility based on potential surprises.

Key Risk

If revenue growth exceeds $21B, it could challenge the current bearish sentiment and shift market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either validate the company's growth trajectory or signal potential challenges ahead.

Bull Confirmed If

An EPS of $7.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $6.00 would confirm the bear case, raising concerns about growth sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±8.56%

Historical Avg

±8.6%

In line with history

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±8.6% while LLY has averaged ±8.6% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

41.6%

Calls (3.2M)P/C Ratio: 0.97Puts (1.4M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Eli Lilly beats expectations, history suggests a stock increase of around 3.77%, confirming the company's strong market position.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to muted stock movement.

Miss

A miss could result in a decline of approximately 8.97%, reflecting investor disappointment and concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House + Senate

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected market impact.
2Details on cost management strategies and their effect on margins.
3Insights into competitive pressures and how Eli Lilly plans to address them.
4Management's outlook on market conditions and potential regulatory impacts.
5Any commentary on long-term growth strategies and pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

$6.55

Revenue

Total revenue is essential for understanding the company's sales performance and growth trajectory.

$20.7B

Wall Street expectations, options signals, track record, and call prep available with Pro.

LLY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.79%

Avg Stock Reaction

+0.58%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Eli Lilly to report strong earnings again, with a consensus EPS of $6.55. Given the company's recent performance, there is optimism about continued revenue growth.

Bull Case

If Eli Lilly exceeds EPS expectations, it could signal robust demand for its products, potentially leading to further stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects, leading to a decline in stock value.

Key Metrics to Watch

EPS

$6.55

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

$20.7B

Total revenue is essential for understanding the company's sales performance and growth trajectory.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Eli Lilly's EPS exceed the consensus estimate of $6.55?

A strong EPS could reinforce investor confidence and lead to a positive stock reaction.

What insights will management provide regarding revenue growth trends?

Understanding revenue drivers will be critical for assessing the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Eli Lilly's ability to leverage recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

Eli Lilly has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing in a significant move, suggesting that investors expect volatility based on potential surprises.

Key Risk

If revenue growth exceeds $21B, it could challenge the current bearish sentiment and shift market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either validate the company's growth trajectory or signal potential challenges ahead.

Bull Confirmed If

An EPS of $7.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $6.00 would confirm the bear case, raising concerns about growth sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±8.56%

Historical Avg

±8.6%

In line with history

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±8.6% while LLY has averaged ±8.6% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

41.6%

Calls (3.2M)P/C Ratio: 0.97Puts (1.4M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Eli Lilly beats expectations, history suggests a stock increase of around 3.77%, confirming the company's strong market position.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to muted stock movement.

Miss

A miss could result in a decline of approximately 8.97%, reflecting investor disappointment and concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House + Senate

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected market impact.
2Details on cost management strategies and their effect on margins.
3Insights into competitive pressures and how Eli Lilly plans to address them.
4Management's outlook on market conditions and potential regulatory impacts.
5Any commentary on long-term growth strategies and pipeline developments.